Health Catalyst, a Salt Lake City-based data warehousing company that’s focused on healthcare, has added $8 million to its Series B round, care of Kaiser Permanente Ventures and CHV Capital. Previously, the company had raised $33 million for its Series B, from investors that include Norwest Venture Partners, Sequoia Capital and Sorenson Capital.

Valeritas Inc., a Bridgewater, N.J.-based developer of drug delivery systems for the diabetes market, has raised $150 million in Series C financing. The funding will support commercialization of its V-Go disposable insulin delivery device. Welsh, Carson, Anderson & Stowe led the financing and assumes a controlling interest in Valeritas. Previous investors MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, ONSET Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures also participated.

Kaiser Permanente Ventures has added two new limited partners, bringing its current fund to $170 million, the firm announced. It has also expanded its team, adding Sam Brasch as a director and Yan Pu as an analyst. Brasch was most recently at Frazier Healthcare Ventures. Pu worked previously in life sciences and healthcare strategy consulting with IMS Health and Navigant Consulting. Kaiser Permanente Ventures invests in medical device, health care service, diagnostic and drug delivery.

Transcend Medical Inc., a Menlo Park, Calif.-based ophthalmic device company, has closed a second tranche of its Series B round, bringing the total to an eye-popping $51 million. Investors include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners. The company says it will use the funds to develop additional infrastructure and resources for a U.S. study of its micro-stent technology. The company is focused on minimally invasive glaucoma therapies.

Life can be hard for young biotechs, but that doesn’t mean the market is sympathetic.  AcelRX Pharmaceuticals of Redwood City, Calif., is the latest biotech to receive a cold reception from investors. After slashing its planned offering price from between $12 and $14 to $5 per share, the stock has been trending downward since its debut [...]

Arcxis Biotechnologies, a privately held biomedical device firm, announced today that it has completed the first close of its Series B round. Claremont Creek Ventures, who led the round, was joined by Kaiser Permanente Ventures and Alafi Capital. These funds will enable Arcxis to accelerate development, testing, and commercialization of their innovative nucleic acid sample [...]